Opportunity Information: Apply for PAR 19 279
The National Cancer Institute (NCI), through the National Institutes of Health, issued this discretionary grant funding opportunity (PAR-19-279) to support research that directly tackles stubborn, under-explored problems in multiple myeloma (MM) disparities. The core idea is built around NCI's "Provocative Questions" approach: instead of broadly funding any MM topic, this announcement points researchers toward a short, curated set of high-need questions where important scientific or real-world paradoxes exist and where the field has not paid enough attention. The goal is to push investigators to develop fresh, practical lines of inquiry that can clarify why disparities occur in MM and how they might be reduced.
Projects submitted under this FOA must be organized around one and only one of the six NCI-defined Multiple Myeloma Disparities Provocative Questions (MMD PQs). In other words, applicants are expected to pick a single PQ from the list and design the entire R01 research plan to answer that specific question. While the opportunity encourages creative thinking and new approaches, it is not meant to cover the full universe of multiple myeloma research priorities. It is intentionally narrow and challenge-driven: the research should aim to resolve a defined disparity-related problem or paradox that NCI has highlighted, rather than proposing a broad exploratory myeloma program.
The mechanism is an R01 research project grant, with clinical trials listed as optional, meaning applicants can propose either non-clinical-trial research or a clinical trial, as long as it is appropriate to the selected provocative question and fits NIH and NCI requirements for rigor, feasibility, and human subjects protections. The FOA also explicitly supports multidisciplinary and transdisciplinary strategies. That means a project can integrate methods and perspectives across fields (for example, tumor biology, genomics, immunology, epidemiology, implementation science, health services research, behavioral science, data science, or community-engaged research), as long as the work stays tightly aligned with the single chosen PQ and does not drift into unrelated aims.
Eligibility is broad and includes many common NIH applicant types such as public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and a range of government entities (state, county, city/township, special districts, independent school districts), as well as public housing authorities/Indian housing authorities and federally recognized tribal governments. Importantly, the FOA highlights additional eligible applicant categories that are especially relevant to disparities-focused work and community reach, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISI). It also calls out faith-based or community-based organizations, non-domestic (non-U.S.) entities (foreign organizations), regional organizations, tribal governments that are not federally recognized, and U.S. territories or possessions, signaling NCI's intent to encourage participation from institutions and communities that are often central to understanding and addressing inequities.
Programmatically, the announcement sits within NIH and NCI cancer research authorities and is associated with several CFDA numbers (93.393, 93.394, 93.395, 93.396, 93.399), reflecting its placement within NCI's broader grant portfolio. While the source information provided does not specify an award ceiling or the expected number of awards, the announcement emphasizes targeted, question-driven R01 projects intended to produce clear advances on defined MM disparities problems. The opportunity was created on May 13, 2019, with an original closing date of November 15, 2020, indicating it was a time-bounded solicitation during that period.
In practical terms, a competitive application under this FOA would be expected to do a few things well: clearly name and quote (or precisely reference) the single selected MMD PQ; explain why the problem is paradoxical or unresolved and why it matters for MM disparities; propose a coherent set of aims that directly answer that question; justify the chosen approach (including any multi-level or cross-disciplinary components) as necessary to solve the specific problem; and, if a clinical trial is included, show that the trial design is ethical, feasible, and tightly linked to the provocative question rather than added as a general clinical study. Overall, the FOA is designed to catalyze focused, high-impact MM disparities research by narrowing the target to a small set of NCI-identified questions and encouraging investigators to bring new tools and perspectives to answers that have remained out of reach.Apply for PAR 19 279
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.395, 93.396, 93.399.
- This funding opportunity was created on 2019-05-13.
- Applicants must submit their applications by 2020-11-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NCI/NIH Discretionary Grant Opportunity PAR-19-279 (Multiple Myeloma Disparities Provocative Questions)
1) What is PAR-19-279 trying to accomplish?
PAR-19-279 is an NCI (through NIH) discretionary funding opportunity designed to support research that directly addresses persistent, under-explored problems related to disparities in multiple myeloma (MM). The focus is not on broad MM research, but on resolving specific disparity-related problems or paradoxes that NCI has flagged as high-need and insufficiently studied.
2) What is the main framework behind this funding opportunity?
The FOA is built around NCI's "Provocative Questions" approach. Instead of inviting any topic within MM, NCI curated a short list of targeted questions where important scientific or real-world paradoxes exist and where the field has not paid enough attention. Applications are expected to be challenge-driven and tightly scoped to those questions.
3) Do applicants have to choose from a set list of questions?
Yes. Projects must be organized around one, and only one, of the six NCI-defined Multiple Myeloma Disparities Provocative Questions (MMD PQs). The entire R01 plan is expected to be built to answer that single selected question.
4) Can an application address more than one Provocative Question?
No. The FOA states that submissions must be organized around a single chosen PQ. A project that tries to cover multiple PQs would not match the structure described for this opportunity.
5) Is this FOA intended to cover all multiple myeloma research priorities?
No. It is intentionally narrow. The FOA is designed to fund focused projects that resolve a defined disparity-related problem or paradox highlighted by NCI, rather than supporting a broad, exploratory, or comprehensive multiple myeloma research program.
6) What grant mechanism is used for this opportunity?
The mechanism is an R01 research project grant.
7) Are clinical trials allowed under PAR-19-279?
Clinical trials are optional. Applicants may propose a clinical trial or a non-clinical-trial study, as long as the approach is appropriate to the selected provocative question and meets NIH/NCI expectations for rigor, feasibility, and human subjects protections.
8) If a clinical trial is included, what does the FOA emphasize?
The FOA emphasizes that any proposed clinical trial should be ethical, feasible, and tightly linked to the selected provocative question. A trial should not be added as a general clinical study that is only loosely connected to the PQ.
9) Does the FOA encourage multidisciplinary or transdisciplinary research?
Yes. The FOA explicitly supports multidisciplinary and transdisciplinary strategies. Projects may integrate methods and perspectives across fields, provided the work stays tightly aligned with the single chosen PQ and does not drift into unrelated aims.
10) What kinds of disciplines or approaches can be integrated in an application?
The FOA notes that projects can draw from areas such as tumor biology, genomics, immunology, epidemiology, implementation science, health services research, behavioral science, data science, and community-engaged research, among others, as long as they remain centered on the single selected PQ.
11) Who is eligible to apply?
Eligibility is broad and includes many typical NIH applicant types: public and private institutions of higher education; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses); small businesses; and a range of government entities (including state, county, city/township, special districts, independent school districts). It also includes public housing authorities/Indian housing authorities and federally recognized tribal governments.
12) Are minority-serving institutions specifically encouraged or named as eligible?
Yes. The FOA explicitly highlights several categories often central to disparities work and community reach, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISI).
13) Can faith-based or community-based organizations apply?
Yes. Faith-based and community-based organizations are called out as eligible applicant categories.
14) Are non-U.S. (foreign) organizations eligible?
Yes. The FOA indicates that non-domestic (non-U.S.) entities (foreign organizations) are eligible.
15) Are regional organizations eligible?
Yes. Regional organizations are included among the eligible applicant categories highlighted in the FOA.
16) Are tribal governments that are not federally recognized eligible?
Yes. The FOA explicitly mentions tribal governments that are not federally recognized as eligible.
17) Are U.S. territories or possessions eligible to apply?
Yes. The FOA signals eligibility for U.S. territories or possessions.
18) What CFDA numbers are associated with this opportunity?
The FOA is associated with several CFDA numbers: 93.393, 93.394, 93.395, 93.396, and 93.399.
19) Does the provided information state the maximum award amount or the expected number of awards?
No. Based on the information provided, an award ceiling and the expected number of awards are not specified.
20) When was this funding opportunity created, and when did it close?
The opportunity was created on May 13, 2019, and the original closing date listed is November 15, 2020, indicating it was time-bounded during that period.
21) What does a competitive application need to do, according to the description provided?
Based on the provided description, a competitive application would be expected to: clearly name and quote (or precisely reference) the single selected MMD PQ; explain why the problem is paradoxical or unresolved and why it matters for MM disparities; propose a coherent set of aims that directly answer the question; justify the chosen approach (including any cross-disciplinary components) as necessary to solve the specific problem; and, if proposing a clinical trial, demonstrate ethical design, feasibility, and tight linkage to the provocative question.
22) What is the main thing applicants should avoid when designing the project?
The main risk implied by the FOA description is drifting into unrelated aims or proposing a broad myeloma research program. The project is expected to remain tightly focused on answering one specific NCI-defined provocative question about MM disparities.
Browse more opportunities from the same category: Education, Health
Next opportunity: Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
Previous opportunity: 2019 Colombia, Ecuador, Venezuela
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 19 279
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 19 279) also looked into and applied for these:
| Funding Opportunity |
|---|
| Digital Health Technologies to Address the Social Determinants of Health in context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) Apply for RFA DA 20 017 Funding Number: RFA DA 20 017 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R21 Clinical Trial Optional) Apply for PAR 19 280 Funding Number: PAR 19 280 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Digital Health Technologies to Address the Social Determinants of Health in context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) Apply for RFA DA 20 018 Funding Number: RFA DA 20 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed) Apply for PAR 19 285 Funding Number: PAR 19 285 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional) Apply for PAR 19 283 Funding Number: PAR 19 283 Agency: National Institutes of Health Category: Education, Health Funding Amount: $280,000 |
| Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed) Apply for PAR 19 284 Funding Number: PAR 19 284 Agency: National Institutes of Health Category: Education, Health Funding Amount: $28,000 |
| Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional) Apply for RFA DA 20 020 Funding Number: RFA DA 20 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) Apply for PAR 19 282 Funding Number: PAR 19 282 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Rapid Assessment of Drug Abuse: Smart City Tools (R43/R44 - Clinical Trial Optional) Apply for RFA DA 20 021 Funding Number: RFA DA 20 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional) Apply for RFA DA 20 013 Funding Number: RFA DA 20 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Workshops on the Use of Adolescent Brain Cognitive Development (ABCD) Data (R25 Clinical Trial Not Allowed) Apply for RFA DA 20 001 Funding Number: RFA DA 20 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional) Apply for PAR 19 287 Funding Number: PAR 19 287 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Clinical Sites (U01 Clinical Trial Required) Apply for RFA HG 19 013 Funding Number: RFA HG 19 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 - Clinical Trial Not Allowed) Apply for RFA DA 20 019 Funding Number: RFA DA 20 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional ) Apply for RFA DA 20 016 Funding Number: RFA DA 20 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $550,000 |
| NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 19 290 Funding Number: PAR 19 290 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 19 291 Funding Number: PAR 19 291 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Clinical Outcome Assessments for Clinical Trials in Substance Use Disorders as FDA-qualified Drug Development Tools (U01 Clinical Trial Optional) Apply for RFA DA 20 015 Funding Number: RFA DA 20 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 - Clinical Trials Not Allowed) Apply for RFA DA 20 009 Funding Number: RFA DA 20 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 - Clinical Trials Not Allowed) Apply for RFA DA 20 008 Funding Number: RFA DA 20 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 19 279", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.